On April 17, 2023 Glycotope GmbH, a biotechnology company utilizing a proprietary platform technology to developing antibodies against proteins carrying tumor-specific carbohydrate structures, reported that it will present its glyco-engineered cell lines in a poster presentation at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Meeting, being held in Orlando, Florida, United States, between 14-19 April 2023 (Press release, Glycotope, APR 17, 2023, View Source [SID1234630152]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Patrik Kehler, Chief Scientific Officer of Glycotope GmbH commented: "Our glyco-engineered cell lines provide the basis for atnew generation of therapeutic antibodies with increased tumor specificity and safety for highly potent therapeutic approaches like ADCs, CARs and radiotherapeutics. Glycotope’s proprietary platform represents a versatile tool for target validation and screening of glycosylation-dependent protein binding antibodies. We look forward to presenting our work at the 2023 AACR (Free AACR Whitepaper) Annual Meeting and discussing our approach with leading cancer research experts."

Poster details are as follows:

Abstract: Download here

Title: Using glyco-engineered cells with flexible expression of tumor-associated carbohydrates for the generation of highly tumor-specific antibodies

Abstract Number: 1588

Session Date and Time: Monday Apr 17, 2023 9:00 AM – 12:30 PM

Location: Poster Section 16, Poster Board Number 11